DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with Perjeta (pertuzumab) for the first-line treatment of adults with unresectable or ...

The combination with Enhertu aims to improve treatment outcomes for HER2-low patients and expand therapeutic options.

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard of care for HER2-positive breast tumors for more than a decade.

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

CX-5461 is the first G-quadruplex (G4) stabilizer in development. It has shown promising activity in early-phase trials for ...

Enhertu (trastuzumab deruxtecan) has now been approved in China for the treatment of adult patients with unresectable or ...

AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved by the US FDA to treat adult patients with unresectable or metastatic HER2-positive breast cancer.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...

WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated ...